Improving Patient Outcomes in Urothelial Carcinoma With Novel Antibody–Drug Conjugates PeerView Oncology 40:12 1 year ago 155 Скачать Далее
The evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma Touch Medical Media Services 31:39 2 years ago 220 Скачать Далее
ADCs for advanced UC and their molecular markers of response VJOncology 0:33 1 year ago 45 Скачать Далее
ADCs in the treatment landscape of patients with advanced UC VJOncology 1:44 1 year ago 79 Скачать Далее
The optimal sequence of ADCs and other therapies in advanced and metastatic urothelial cancer VJOncology 1:11 1 year ago 71 Скачать Далее
Novel combined ADCs in metastatic urothelial carcinoma: insights from ESMO 2023 VJOncology 0:38 9 months ago 64 Скачать Далее
Sequencing ADCs and finding novel biomarkers for urothelial carcinoma VJOncology 0:46 6 months ago 27 Скачать Далее
The future of antibody-drug conjugates in urothelial cancer VJOncology 2:30 6 months ago 82 Скачать Далее
How effective are ADCs in treating metastatic urothelial cancer? VJOncology 3:06 1 year ago 124 Скачать Далее
Enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma VJOncology 0:30 1 year ago 386 Скачать Далее
Where do ADCs fit in the treatment landscape of urothelial carcinoma? VJOncology 0:54 6 months ago 37 Скачать Далее
What are the latest in ADCs for prostate and bladder cancer? VJOncology 2:19 1 year ago 293 Скачать Далее
Sequencing and treatment strategies in advanced urothelial carcinoma VJOncology 1:26 1 month ago 31 Скачать Далее
UNITE: enfortumab vedotin in advanced urothelial cancer VJOncology 4:16 3 years ago 171 Скачать Далее
Advanced/Metastatic Urothelial Carcinoma: Understanding Novel Immunotherapy Maintenance Strategies PeerView Oncology 56:13 2 years ago 241 Скачать Далее
